HFpEF is rapidly increasing in incidence and prevalence, accounting for approximately 50% of all new cases of heart failure. It has a significant impact on patients’ quality of life and is associated with a high risk of hospitalization and death. The diagnosis of HFpEF is challenging, and many patients with HFpEF are likely to be unrecognized or misdiagnosed. So far, HFpEF management relies on patient education and treatment of comorbidities. However, the use of SGLT-2 inhibitors has recently demonstrated a significant reduction in the composite outcome of heart failure hospitalizations and cardiovascular mortality in HFpEF, and is now considered as the first-line therapy.
